Omeros (OMER) Capital Expenditures (2010 - 2025)
Omeros recorded quarterly Capital Expenditures of $11000.0 in Q3 2025, down 15.38% quarter-over-quarter from $13000.0 in Q2 2025, and up 1000.0% year-over-year from $1000.0 in Q3 2024.
Omeros' Capital Expenditures history runs 16 years deep, the most recent figure standing at $11000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures rose 1000.0% year-over-year to $11000.0; the TTM figure through Mar 2026 stood at $24000.0 (down 83.78% YoY), while the FY2025 annual figure was $65000.0, down 60.61% from the prior year.
- Capital Expenditures came in at $11000.0 for Q3 2025 at Omeros, down from $13000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $275000.0 in Q2 2023 to a low of -$3000.0 in Q3 2022.
- A 5-year average of $58937.5 and a median of $37000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures tumbled 102.91% in 2022 and jumped 1200.0% in 2023, its largest moves.
- Omeros' Capital Expenditures stood at $74000.0 in 2021, then tumbled by 82.43% to $13000.0 in 2022, then surged by 807.69% to $118000.0 in 2023, then tumbled by 77.97% to $26000.0 in 2024, then slumped by 57.69% to $11000.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $11000.0, $13000.0, and $41000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 11,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Mar 31, 2025 | 41,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Sep 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Mar 31, 2024 | 58,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Dec 31, 2023 | 118,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Sep 30, 2023 | 33,000.00 |
| Jun 30, 2023 | 275,000.00 |
| Jun 30, 2023 | 275,000.00 |
| Dec 31, 2022 | 13,000.00 |
| Dec 31, 2022 | 13,000.00 |
| Sep 30, 2022 | -3,000.00 |
| Sep 30, 2022 | -3,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Sep 30, 2021 | 103,000.00 |
| Jun 30, 2021 | 88,000.00 |
| Jun 30, 2021 | 88,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Sep 30, 2020 | 73,000.00 |
| Sep 30, 2020 | 73,000.00 |
| Jun 30, 2020 | 144,000.00 |
| Jun 30, 2020 | 144,000.00 |
| Mar 31, 2020 | 66,000.00 |
| Mar 31, 2020 | 66,000.00 |
| Dec 31, 2019 | 16,000.00 |
| Dec 31, 2019 | 16,000.00 |
| Sep 30, 2019 | 39,000.00 |
| Sep 30, 2019 | 39,000.00 |
| Jun 30, 2019 | 97,000.00 |
| Jun 30, 2019 | 97,000.00 |
| Mar 31, 2019 | 182,000.00 |
| Mar 31, 2019 | 182,000.00 |
| Dec 31, 2018 | 93,000.00 |
| Dec 31, 2018 | 93,000.00 |
| Sep 30, 2018 | 88,000.00 |
| Sep 30, 2018 | 88,000.00 |
| Jun 30, 2018 | 203,000.00 |
| Jun 30, 2018 | 203,000.00 |
| Mar 31, 2018 | 183,000.00 |
| Mar 31, 2018 | 183,000.00 |
| Sep 30, 2017 | 34,000.00 |
| Sep 30, 2017 | 34,000.00 |
| Jun 30, 2017 | 244,000.00 |
| Jun 30, 2017 | 244,000.00 |
| Mar 31, 2017 | 72,000.00 |
| Mar 31, 2017 | 72,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Dec 31, 2016 | 48,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Sep 30, 2016 | 44,000.00 |
| Jun 30, 2016 | 34,000.00 |
| Jun 30, 2016 | 34,000.00 |
| Dec 31, 2015 | 53,000.00 |
| Dec 31, 2015 | 53,000.00 |
| Sep 30, 2015 | 73,000.00 |
| Sep 30, 2015 | 73,000.00 |
| Jun 30, 2015 | 114,000.00 |
| Jun 30, 2015 | 114,000.00 |
| Dec 31, 2014 | 16,000.00 |
| Dec 31, 2014 | 16,000.00 |
| Sep 30, 2014 | 10,000.00 |
| Sep 30, 2014 | 10,000.00 |
| Jun 30, 2014 | -4,000.00 |
| Jun 30, 2014 | -4,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Dec 31, 2013 | 67,000.00 |
| Dec 31, 2013 | 67,000.00 |
| Sep 30, 2013 | 48,000.00 |
| Sep 30, 2013 | 48,000.00 |
| Jun 30, 2013 | 1,000.00 |
| Jun 30, 2013 | 1,000.00 |
| Mar 31, 2013 | 88,000.00 |
| Mar 31, 2013 | 88,000.00 |
| Dec 31, 2012 | 407,000.00 |
| Dec 31, 2012 | 407,000.00 |
| Sep 30, 2012 | 90,000.00 |
| Sep 30, 2012 | 90,000.00 |
| Jun 30, 2012 | 73,000.00 |
| Jun 30, 2012 | 73,000.00 |
| Mar 31, 2012 | 72,000.00 |
| Mar 31, 2012 | 72,000.00 |
| Dec 31, 2011 | 41,000.00 |
| Dec 31, 2011 | 41,000.00 |
| Sep 30, 2011 | 7,000.00 |
| Sep 30, 2011 | 7,000.00 |
| Jun 30, 2011 | 511,000.00 |
| Jun 30, 2011 | 511,000.00 |
| Mar 31, 2011 | 682,000.00 |
| Mar 31, 2011 | 682,000.00 |
| Dec 31, 2010 | 48,000.00 |
| Dec 31, 2010 | 48,000.00 |
| Sep 30, 2010 | 154,000.00 |
| Sep 30, 2010 | 154,000.00 |